Ashley Stark1, P Brian Smith2, Christoph P Hornik2, Kanecia O Zimmerman2, Chi D Hornik1, Sidart Pradeep3, Reese H Clark4, Daniel K Benjamin2, Matthew Laughon5, Rachel G Greenberg6. 1. Department of Pediatrics, Duke University School of Medicine, Durham, NC. 2. Department of Pediatrics, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. 3. University of Texas Health San Antonio, San Antonio, TX. 4. MEDNAX, Inc, Sunrise, FL. 5. Department of Pediatrics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC. 6. Department of Pediatrics, Duke University School of Medicine, Durham, NC; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. Electronic address: rachel.greenberg@duke.edu.
Abstract
OBJECTIVE: To provide up-to-date medication prescribing patterns in US neonatal intensive care units (NICUs) and to examine trends in prescribing patterns over time. STUDY DESIGN: We performed a cohort study of 799 016 infants treated in NICUs managed by the Pediatrix Medical Group from 2010 to 2018. We used 3 different methods to report counts of medication: exposure, courses, and days of use. We defined the change in frequency of medication administration by absolute change and relative change. We examined the Food and Drug Administration (FDA) package insert for each medication to determine whether a medication was labeled for use in infants and used PubMed to search for pharmacokinetics (PK) studies. RESULTS: The most frequently prescribed medications included ampicillin, gentamicin, caffeine citrate, poractant alfa, morphine, vancomycin, furosemide, fentanyl, midazolam, and acetaminophen. Of the top 50 medications used in infants with extremely low birth weight, only 20 (40%) are FDA-labeled for use in infants; of the 30 that are not labeled for use in infants, 13 (43%) had at least 2 published PK studies. The medications with the greatest relative increase in use from 2010 to 2018 included dexmedetomidine, clonidine, rocuronium, levetiracetam, atropine, and diazoxide. The medications with the greatest relative decrease in use included tromethamine acetate, pancuronium, chloral hydrate, imipenem + cilastatin, and amikacin. CONCLUSION: Trends of medication use in the NICU change substantially over time. It is imperative to identify changes in medication use in the NICU to better inform further prospective studies.
OBJECTIVE: To provide up-to-date medication prescribing patterns in US neonatal intensive care units (NICUs) and to examine trends in prescribing patterns over time. STUDY DESIGN: We performed a cohort study of 799 016 infants treated in NICUs managed by the Pediatrix Medical Group from 2010 to 2018. We used 3 different methods to report counts of medication: exposure, courses, and days of use. We defined the change in frequency of medication administration by absolute change and relative change. We examined the Food and Drug Administration (FDA) package insert for each medication to determine whether a medication was labeled for use in infants and used PubMed to search for pharmacokinetics (PK) studies. RESULTS: The most frequently prescribed medications included ampicillin, gentamicin, caffeine citrate, poractant alfa, morphine, vancomycin, furosemide, fentanyl, midazolam, and acetaminophen. Of the top 50 medications used in infants with extremely low birth weight, only 20 (40%) are FDA-labeled for use in infants; of the 30 that are not labeled for use in infants, 13 (43%) had at least 2 published PK studies. The medications with the greatest relative increase in use from 2010 to 2018 included dexmedetomidine, clonidine, rocuronium, levetiracetam, atropine, and diazoxide. The medications with the greatest relative decrease in use included tromethamine acetate, pancuronium, chloral hydrate, imipenem + cilastatin, and amikacin. CONCLUSION: Trends of medication use in the NICU change substantially over time. It is imperative to identify changes in medication use in the NICU to better inform further prospective studies.
Authors: Kate O'Hara; Ian M R Wright; Jennifer J Schneider; Alison L Jones; Jennifer H Martin Journal: Br J Clin Pharmacol Date: 2015-10-26 Impact factor: 4.335
Authors: Michael Zayek; Jayalakshmi Bhat; Katie Bonner; Michelle Blake; Keith Peevy; Om Prakash Jha; Rashmi Gulati; Ramachandra Bhat Journal: Pediatr Qual Saf Date: 2020-07-07
Authors: Alexander G Agthe; George R Kim; Kay B Mathias; Craig W Hendrix; Raul Chavez-Valdez; Lauren Jansson; Tamorah R Lewis; Myron Yaster; Estelle B Gauda Journal: Pediatrics Date: 2009-04-27 Impact factor: 7.124
Authors: Andrea Trembath; Christoph P Hornik; Reese Clark; P Brian Smith; Julie Daniels; Matthew Laughon Journal: J Pediatr Date: 2013-06-12 Impact factor: 4.406
Authors: Athena F Zuppa; Susan C Nicolson; Nicole S Wilder; Juan C Ibla; Erin A Gottlieb; Kristin M Burns; Mario Stylianou; Felicia Trachtenberg; Hua Ni; Tera H Skeen; Dean B Andropoulos Journal: Br J Anaesth Date: 2019-10-14 Impact factor: 11.719
Authors: Alcidésio Sales de Souza; Djanilson Barbosa Dos Santos; Luís Carlos Rey; Marina Garruti Medeiros; Marta Gonçalves Vieira; Helena Lutéscia Luna Coelho Journal: BMC Pediatr Date: 2016-01-21 Impact factor: 2.125
Authors: David J McCulley; Erik A Jensen; Jennifer M S Sucre; Sarah McKenna; Laura G Sherlock; Evgenia Dobrinskikh; Clyde J Wright Journal: Am J Physiol Lung Cell Mol Physiol Date: 2022-05-03 Impact factor: 6.011
Authors: Nadir Yalçın; Merve Kaşıkcı; Hasan Tolga Çelik; Karel Allegaert; Kutay Demirkan; Şule Yiğit; Murat Yurdakök Journal: J Clin Med Date: 2022-08-12 Impact factor: 4.964
Authors: Helen M Nabwera; Osayame A Ekhaguere; Haresh Kirpalani; Kathy Burgoine; Chinyere V Ezeaka; Walter Otieno; Stephen J Allen; Nicholas D Embleton Journal: BMJ Glob Health Date: 2021-12